** Shares of heart company Anteris Technologies AVR.O
slide 12.3% to $5.26 in their Nasdaq debut
** Stock opened for trading at $6, valuing the company at
$215.6 mln
** AVR sold 14.8 mln shares in its New York IPO at $6/shr to
raise $88.8 mln
** Offering priced at a 11.5% discount to the Dec. 5 closing
price of its shares on the Australian Securities Exchange
** TD Cowen, Barclays and Cantor were the joint book-running
managers for the offering
** AVR will use the proceeds to fund the development of its
transcatheter heart valve, among other purposes
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com))